个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Chu, Q.[1] * ; Jiang, J.[1] ; Huang, S.[1] ; Zhang, P.[1] ; Chen, Y.[1] ;
单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
出处：
DOI： 10.1016/j.jtho.2018.08.1852
ISSN：

关键词： EGFR de novo MET bevacizumab

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 呼吸系统
最新[2025]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 呼吸系统
JCR分区：
出版当年[2016]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM
最新[2023]版：
Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2015版] 出版后一年[2017版]

第一作者：
第一作者单位： [1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China
推荐引用方式(GB/T 7714)：
Chu Q.,Jiang J.,Huang S.,et al.A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab[J].JOURNAL OF THORACIC ONCOLOGY.2018,13(10):S980-S981.doi:10.1016/j.jtho.2018.08.1852.
APA：
Chu, Q.,Jiang, J.,Huang, S.,Zhang, P.&Chen, Y..(2018).A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab.JOURNAL OF THORACIC ONCOLOGY,13,(10)
MLA：
Chu, Q.,et al."A Lung Adenocarcinoma with Concomitant EGFR and de novo MET Amplification Response Well to Combination of TKI and Bevacizumab".JOURNAL OF THORACIC ONCOLOGY 13..10(2018):S980-S981

相关文献

[1]A Lung Adenocarcinoma with Concomitant EGFR And De Novo MET Amplification Response Well to Combination of TKI And Bevacizumab [2]CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC [3]Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study [4]LRIG1过表达对神经胶质瘤细胞EGFR信号传导的抑制作用 [5]EGFR-TKIs resistance via EGFR-independent signaling pathways [6]Comparison of intra-pleural injection efficacy between Endostar and Bevacizumab combined with pemetrexed/cisplatin for the treatment of malignant pleural effusion in patients with epidermal growth factor receptor-/anaplastic lymphoma kinase-lung adenocarci [7]Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study) [8]A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ? Bevacizumab versus FOLFOX ? Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study) [9]培美曲塞+奈达铂联合贝伐珠单抗治疗后行培美曲塞联合贝伐珠单抗维持治疗在晚期非鳞非小细胞肺癌中的疗效与安全性分析 [10]A randomized, open-label, multicenter, phase 3 study of high-dose vitamin C plus FOLFOX +/- bevacizumab versus FOLFOX +/- bevacizumab in unresectable untreated metastatic colorectal cancer

资源点击量：426 今日访问量：0 总访问量：408 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）